Approximately 1 in 5 patients with breast cancer have HER2-positive cancer, an especially aggressive form of the disease. Genentech has developed targeted therapies (Herceptin®, Perjeta® Kadcyla®) to treat patients with HER2+ breast cancer. The advent of these promising, breakthrough therapies represents a significant milestone in the HER2+ breast cancer medicine development journey.
A diagnosis of HER2+ breast cancer can be overwhelming. Patients have questions about their disease,
their treatment, as well as everyday matters such as diet, exercise and how to talk with family and friends.
There was a crucial need to provide patients with comprehensive information and on-going support
as they undergo treatment.
Engage patients at the point of care. HER2+ breast cancer patients who are undergoing
treatment spend many hours at the infusion center, seated in the treatment chair.
The 4HER app puts relevant information and much needed support right at patients’ fingertips.
The 4HER app provides information about HER2+ breast cancer and targeted treatments. It also helps patients relax and de-stress with soothing guided meditations and a fun game. In addition, 4HER enables patients to easily connect with other HER2+ patients, nurses and support groups.